TNDM TANDEM DIABETES CARE INC

Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR

TANDEM DIABETES CARE INC (TNDM) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • New risk: CMS proposed competitive bidding process and payment changes for insulin pumps (June 30, 2025) could reduce reimbursement and impact revenue recognition
  • Updated competitive risk: Increased adoption of GLP-1 drugs since 2023 negatively impacts insulin therapy market demand
+3 more insights

Get deeper insights on TANDEM DIABETES CARE INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.